How Is NK Cell Therapy Regulated in Japan? A Guide for Overseas Patients

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

If you are researching NK cell therapy from outside Japan, one of the first practical questions is how the treatment is regulated. Cell-based treatments are not all handled the same way from country to country, and knowing which rules apply helps you ask better questions before you travel. This article explains, in general terms, how NK cell therapy fits into the Japanese regulatory framework for regenerative medicine, and what that means for international patients who are considering a consultation at Grand Green Osaka Umekita Clinic in Osaka.

The short answer: a legal framework exists, but it does not replace your own questions

In Japan, cell-based treatments of this kind are generally provided under the Act on the Safety of Regenerative Medicine (often called the ASRM). Under this system, a clinic that wants to offer a specific cell therapy prepares a treatment plan, has it reviewed by a certified committee, and submits it to the Ministry of Health, Labour and Welfare. The cells are processed at a facility that is itself registered or licensed for that purpose.

That structure is meant to add oversight, transparency, and documentation. It does not mean a treatment is guaranteed to work for any particular person, and it does not remove the need for an individual medical assessment. NK cell therapy is a self-pay (non-insured) treatment in Japan, so it is not covered by the national health insurance system. Costs, risks, possible side effects, and whether the therapy is appropriate for you must all be confirmed with a physician during a consultation.

What the Act on the Safety of Regenerative Medicine is designed to do

The ASRM was introduced to allow regenerative and cell-based treatments to be offered in clinical practice while keeping a system of checks in place. In broad terms, the framework addresses several areas.

• Review of the treatment plan by a certified committee of experts before it is submitted.
• Submission of the plan to the national health authority, with the plan details made available through an official system.
• Requirements for the facility that cultures and processes the cells, including quality management.
• Informed consent procedures, so patients receive an explanation of the treatment, its uncertainties, and its risks.
• Reporting obligations if health problems related to the treatment occur.

The practical point for patients is that the treatment you are offered should correspond to a specific plan that has been reviewed and submitted. It is reasonable to ask a clinic which plan covers the therapy, which kind of cancer or condition it is intended for, and how the cells will be handled.

How this applies to NK cell therapy

NK (natural killer) cells are a type of immune cell that circulates in the blood. In NK cell therapy at Grand Green Osaka Umekita Clinic, a patient’s own cells are collected through a standard blood draw, activated and expanded at a specialized processing facility, and then returned by intravenous infusion. Because the cells come from the patient, the therapy is described as autologous.

Using your own cells generally lowers the concern about rejection, and serious side effects have rarely been reported with this approach. However, temporary reactions such as fever or fatigue can occur, and nobody can promise how a given person will respond. The therapy is also not a replacement for standard cancer treatment. It is intended to be considered alongside the care you are already receiving, and the clinic can coordinate with the medical institution that provides your standard treatment when that is appropriate.

Scientific interest in NK cells is real, and researchers continue to study how they recognize and respond to abnormal cells. At the same time, the evidence for any specific cell therapy is still developing, and results from laboratory work or small studies should not be read as proof of benefit for an individual patient. That is one reason a careful, individual discussion with a doctor matters.

Questions worth asking before you travel to Osaka

Regulation tells you how a treatment is supposed to be provided, but it is your questions that let you judge whether it fits your situation. Before booking a trip, consider preparing the following.

• Which regenerative medicine plan covers the therapy, and can the clinic explain it in a language you understand?
• Is the therapy appropriate for your type and stage of cancer, or for your goal, such as health maintenance after treatment?
• How would it fit with your current or planned surgery, chemotherapy, or radiation therapy?
• What are the fees, how many sessions are typically recommended, and over what period?
• What risks and possible side effects should you expect, and what happens if a problem occurs after you return home?
• Can your home doctor receive a summary of what was done, so your care stays coordinated?

Bringing recent medical records, imaging reports, and a list of your current medications can make the first conversation more useful. A clear picture of your overall treatment plan also helps the doctor give a more grounded opinion.

Support for international patients in Osaka

Grand Green Osaka Umekita Clinic is located in the Umeda area of Osaka, which is easy to reach from Kansai International Airport and from major rail lines. The clinic provides information pages in multiple languages, including English, so that international patients and people living in Japan can review the basics of NK cell therapy before making contact. These pages are an introduction only. They cannot replace a consultation, and they do not describe what any individual patient should expect.

If you are considering medical travel, it is sensible to plan for more than the treatment itself. Think about how long you may need to stay, how you will communicate with your home doctor, and what follow-up you may need after you return. Asking these questions early can prevent surprises later.

Key takeaways

NK cell therapy in Japan is provided under a regulatory framework that involves committee review, notification to the national authority, and controlled cell processing. This framework adds structure and transparency, but it does not guarantee any outcome, and it does not make the therapy a substitute for standard cancer care. The treatment is self-pay, and the fees, risks, side effects, and suitability for you must be confirmed by a physician. If you would like to learn more, the English information page for NK cell therapy at Grand Green Osaka Umekita Clinic is a good place to start, followed by a consultation with a doctor who can review your situation.

• Plan reviewedCommittee review and filing
• Alongside standard care
• Doctor confirmsFees, risks, suitability
• Plan your tripRecords and follow-up

This diagram is a conceptual summary of the article content

References

• PMC: Regulatory Challenges and Opportunities for Cell-Derived Extracellular Vesicles in Pharmaceutical Development: A European and Global Perspective. (2026)
• PMC: Comparative analysis of regulations and studies on stem cell therapies: focusing on induced pluripotent stem cell (iPSC)-based treatments. (2024)
• PMC: Unlocking the therapeutic potential: odyssey of induced pluripotent stem cells in precision cell therapies. (2024)
• PMC: Establishment of an efficient ex vivo expansion strategy for human natural killer cells stimulated by defined cytokine cocktail and antibodies against natural killer cell activating receptors. (2022)
• MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.